000144570 001__ 144570
000144570 005__ 20240229112629.0
000144570 0247_ $$2doi$$a10.1080/15384047.2019.1647057
000144570 0247_ $$2pmid$$apmid:31423907
000144570 0247_ $$2ISSN$$a1538-4047
000144570 0247_ $$2ISSN$$a1538-4077
000144570 0247_ $$2ISSN$$a1555-8576
000144570 0247_ $$2altmetric$$aaltmetric:65175356
000144570 037__ $$aDKFZ-2019-02013
000144570 041__ $$aeng
000144570 082__ $$a610
000144570 1001_ $$00000-0002-1607-1386$$aLou, Emil$$b0
000144570 245__ $$aDifferential response of SHH-expressing adult medulloblastomas to the sonic hedgehog inhibitor vismodegib: whole-genome analysis.
000144570 260__ $$aGeorgetown, Tex.$$bLandes Bioscience$$c2019
000144570 3367_ $$2DRIVER$$aarticle
000144570 3367_ $$2DataCite$$aOutput Types/Journal article
000144570 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1577110086_18928
000144570 3367_ $$2BibTeX$$aARTICLE
000144570 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000144570 3367_ $$00$$2EndNote$$aJournal Article
000144570 500__ $$a20(11):1398-1402.
000144570 520__ $$aMedulloblastoma is an aggressive primitive neuroectodermal tumor of the cerebellum that is more common in children than in adults. In the past decade, advances in understanding the molecular drivers of medulloblastoma have identified four molecular subgroups defined by experimental gene expression profiles: the WNT pathway, sonic hedgehog (SHH) pathway, and subgroups 3 and 4 (non-SHH/WNT).  Medulloblastoma of adults belong primarily to the SHH category. Vismodegib, an SHH-pathway inhibitor, FDA-approved in 2012 for treatment of basal cell carcinoma, has been used successfully in the setting of chemorefractory medulloblastoma, but not as a first-line therapy. In 2016, we reported a case of an adult patient with a sustained response of an unresectable multifocal form of adult medulloblastoma to vismodegib. Molecular analysis in that case revealed mutations in TP53 and a cytogenetic abnormality, i17q, that is prevalent and most often associated with subgroup 4 rather than the SHH-activated form of medulloblastoma. Here, we report further whole-genome analysis of that patient (designated Patient A) as well as an additional adult patient (Patient B) whose tumor harbored the SHH molecular subgroup but which was unresponsive to visgmodegib therapy. Comparison of these disparate responses highlights the challenges to tailoring SHH-targeted treatment in individual patients with adult medulloblastoma.
000144570 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000144570 588__ $$aDataset connected to CrossRef, PubMed,
000144570 7001_ $$aNelson, Andrew C$$b1
000144570 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b2$$eLast author$$udkfz
000144570 773__ $$0PERI:(DE-600)2088895-8$$a10.1080/15384047.2019.1647057$$gp. 1 - 5$$n11$$p1398-1402$$tCancer biology & therapy$$v20$$x1555-8576$$y2019
000144570 909CO $$ooai:inrepo02.dkfz.de:144570$$pVDB
000144570 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000144570 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000144570 9141_ $$y2019
000144570 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000144570 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000144570 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000144570 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER BIOL THER : 2017
000144570 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000144570 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000144570 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000144570 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000144570 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000144570 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000144570 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000144570 980__ $$ajournal
000144570 980__ $$aVDB
000144570 980__ $$aI:(DE-He78)B062-20160331
000144570 980__ $$aI:(DE-He78)L101-20160331
000144570 980__ $$aUNRESTRICTED